UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-40128 biote Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 85-1791125 (State ...

Biote Corp. (BTMD) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.10, delivering a surprise of 11.11%. There are no easy answers to this key quest ...

biote Corp (BTMD) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Hello, and welcome to the Biodi First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Simon Sarovietki. Please go ahead. Speaker1 Thank you for joining us today. This afternoon, Bati published financial results for the fir ...

Biote Reports First Quarter 2025 Financial Results Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights • Revenue of $49.0 million IRVING, TX – May 7, 2025 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-40128 biote Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 85-1791125 (State of i ...

biote Corp. (NASDAQ:BTMD) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Corporate Participants Szymon Serowiecki - Investor Relations Mark Beard - Executive Chairman Bret Christensen - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Jeff Van Sinderen - B. Riley George Kelly - ROTH Capital Partners Alex Fuhrman - Craig-Hallum Capital Group Operator Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conferen ...

Provides fiscal 2025 outlook IRVING, TX – March 12, 2025 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Full Year 2024 Financial Highlights Exhibit 99.1 Biote Reports Fourth Quarter and ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has biote Corp. (BTMD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.biote Corp. is one of 1021 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks w ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Shares of biote Corp. (BTMD) have gained 27% over the past four weeks to close the last trading session at $6.63, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $9.54 indicates a potential upside of 43.9%.The average comprises five short-term price targets ranging from a low of $8 to a high of $11, with a standard deviation of $1.12. While the lowest estimate indicates an incre ...